Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

PAST TOP PICK

(A Top Pick Dec 22/08. Up 12.92%.)

BUY

Great holding. Gives you a piece of pharma, consumer goods and medical devices. 3.2% dividend. Trades at a reasonable multiple.

DON'T BUY

Great leadership name. Trading at around 12X forward earnings. Healthcare stocks tend not to do well when the market starts moving up. Quarterly estimates are being revised downwards. 3.25% dividend. Would prefer Pfizer (PFE-N).

PAST TOP PICK

(A Top Pick Oct 23/08. No change.) Still likes. Not just a pharmaceutical company but also consumer and medical devices businesses. Great balance sheet. 3%+ dividend. Historically has done a great job of growing its equity 10%-15%. Great core holding.

WAIT

(Market Call Minute.) Probably not a Buy for the next 3 or 4 months but longer-term it would be a buy.

PAST TOP PICK

(A Top Pick Sept 3/08. Down 15%.) Made a V base. 200-day moving average around $55. Would love to buy if it broke into new highs. Anything above $62-$63 would be confirmation of the beginning of a new leg.

BUY

Household brand company with a tremendous franchise. Solid balance sheet and solid dividend. No matter what happens, it is not going to hurt you too badly. Be aware that on dividends outside Canada, you pay a lot more tax.

BUY ON WEAKNESS

Probably one of the best US pharmaceuticals. Also have consumer products. Steady earnings and dividend growth for over 20 years. The only risk is the currency effect by investing in a US company. Would like it at $57-$58.

TOP PICK

Healthcare space so is reasonably defensive. Well diversified including consumer products, prescription drugs and medical devices. Fantastic balance sheet management. About a 4% yield. History of increasing dividends.

PAST TOP PICK

(A Top Pick July 3/09. Up 7.31%.) Likes the diverse products in their pharmaceutical and medical devices as well as their consumer products area. Still a Buy.

TOP PICK

Sector most out of favour right now is healthcare. This is one of the most respected companies in the world with a very strong balance sheet. A leader in all its businesses. Wonderful consumer business. Very cheap with a 14 multiple.

BUY

Consumer discretionary and pharmaceuticals. A premier in its class. It does well when the US$ depreciates because of all their sales outside of the country. Good defensive play. Very good free cash flow. 3.2% yield.

PAST TOP PICK

(A Top Pick Aug 5/08. Down 12.21%.)

BUY

Large-cap fully integrated global pharmaceutical. Earnings beat expectations. Competition from generics but their pipeline going forward looks extremely robust.

BUY

Consumer staples, pharmaceuticals, utilities and telecoms have been have been enormous under performers during this rally. Rock solid. Pretty decent dividend.

Showing 466 to 480 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)